Related Experiment Video
Updated: May 24, 2026
09:52
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
A first case of hepatic angiosarcoma treated with recombinant interleukin-2
Fukiko Mitsui1, Hiroshi Aikata, Yoshimasa Hashimoto
1Department of Medicine and Molecular Science, Graduate School of Biomedical Science, Hiroshima University, Hiroshima, Japan.
Hiroshima Journal of Medical Sciences
|March 7, 2012
Summary
A liver tumor initially diagnosed as epithelioid hemangioendothelioma was confirmed as angiosarcoma post-mortem. This case highlights diagnostic challenges and explores recombinant interleukin-2 for hepatic angiosarcoma.
Area of Science:
- Oncology
- Pathology
- Immunotherapy
Background:
- Epithelioid hemangioendothelioma and angiosarcoma are rare liver tumors with overlapping imaging and biopsy features.
- Hepatic angiosarcoma often presents at an advanced stage, posing treatment challenges.
- Recombinant interleukin-2 has shown efficacy in cutaneous angiosarcoma but not hepatic angiosarcoma.
Observation:
- A 60-year-old woman presented with multiple liver tumors, initially diagnosed as epithelioid hemangioendothelioma with metastases.
- Despite treatment with hepatic arterial infusion of recombinant interleukin-2, the patient developed liver failure and died.
- Autopsy revealed the liver tumor to be angiosarcoma, underscoring diagnostic difficulties.
Findings:
- Distinguishing between epithelioid hemangioendothelioma and angiosarcoma based on imaging and percutaneous biopsy is challenging.
- Autopsy confirmation of angiosarcoma is common due to early-stage diagnostic limitations.
- This case represents the first reported instance of hepatic angiosarcoma treated with recombinant interleukin-2.
Implications:
- The findings suggest a need for improved diagnostic methods for differentiating these liver tumors.
- This case provides preliminary data on the potential, albeit unproven, use of recombinant interleukin-2 for hepatic angiosarcoma.
- Further research is warranted to explore immunotherapy's role in managing hepatic angiosarcoma.
